Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
What is the half-life of BPC-157
Lipotropic: Insulin Sensitization Inositol is a documented insulin sensitizer supporting glucose regulation and metabolic efficiency
It is typically administered subcutaneously once daily, with dosages gradually increasing over an 8-12 week cycle to support body composition improvements
The Fat Loss Mechanism The proposed fat loss mechanism of 5-amino-1MQ operates through several interrelated effects: NNMT inhibition preserves SAM and NAD+ pools Increased NAD+ supports sirtuin activity and mitochondrial function Reduced lipogenesis adipocyte fatty acid synthesis is decreased Enhanced adipocyte metabolism improved adipose tissue function Selective effect on adipocytes relative sparing of other tissues Preclinical studies have shown that 5-amino-1MQ treatment in mice produces: Reduced body fat mass Improved insulin sensitivity Preserved lean mass Favorable effects on liver fat in diet-induced obesity models The Human Clinical Trials Picture As of 2026, human clinical trial activity for 5-amino-1MQ is emerging but not yet mature
